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Background. Tuberculosis (TB) is a cause of significant morbidity and mortality in patients with AIDS. The goal of our study was
to determine predictors of in-hospital mortality in patients with AIDS and disseminated tuberculosis in a middle-income country.
Material and Methods. We conducted a retrospective cohort study in a tertiary care center, for patients with AIDS in southern
Brazil. From 1996 to 2008, all patients with the diagnosis of disseminated TB were included. Results. Eighty patients were included.
In-hospital mortality was 35% (N = 28). On multivariate Cox regression analysis, low basal albumin (P < .01) was associated
with death, and fever at admission was related to better survival (P < .01). Conclusion. Albumin levels or fever are independent
predictors of survival in patients with HIV and disseminated TB. They can serve as indirect markers of immunodeficiency in
patients with disseminated TB and AIDS.
1. Introduction
The advent of highly active antiretroviral therapy (HAART)
has changed the natural history of most opportunistic
infections and reduced mortality rates in patients with AIDS
[1, 2]. For Mycobacteria tuberculosis (MTB) disease, several
studies have demonstrated the protective effect of HAART,
in HIV-infected patients [3–6]. However, tuberculosis (TB)
is still a potentially fatal complication in these patients [7,
8].
Several risk factors are associated with elevated risk of
death in patients with TB: advanced age, drug resistance,
delayed specific therapy, lack of rifampicin use, inadequate
therapy, and HIV infection [9–11]. Few studies addressed
this risk in patients with HIV and disseminated TB [12,
13]. The goal of our study was to determine predictors
of in-hospital mortality in patients with AIDS and strictly
disseminated TB.
2. Material and Methods
2.1. Study Population. We performed a retrospective cohort
study at Hospital de Clı́nicas de Porto Alegre, a 740-bed
tertiary referral hospital for persons with AIDS in southern
Brazil. From 1996 to 2008, all persons who attended as
inpatient and had the diagnosis of HIV infection and
disseminated TB were included. Patients were selected from
the review of microbiology laboratory records, and data were
collected by the review of patient’s charts. The study was
approved by the ethics committee of Hospital de Clı́nicas de
Porto Alegre.
2.2. Definitions. Disseminated tuberculosis was defined as
identification of MTB in blood, or bone marrow, or liver
biopsy cultures, as suggested by Wang et al. [14]. Only culture
positive subjects were included.
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The diagnosis of HIV was made according to current
recommendations. For isolation of mycobacteria [15, 16], a
radiometric system (BACTEC 460 TB—Becton & Dickinson
Diagnostic Instrument Systems, Sparks, MD, USA), and
nonradiometric systems (BACTEC 9240—Becton & Dick-
inson Diagnostic Instrument Systems, Sparks, MD, USA;
and, BacT/Alert 240—bioMérieux, Marcy-Etoile, France)
were used. For identification of MTB, NAP (p-nitro-
alfa-acetylamino-beta-hydroxypropiophenone) test was per-
formed. This test has specificity of 99% of the identification
of Mycobacterium tuberculosis complex [17]. In cases which
NAP test could not be done (N = 19, 23%), the identifica-
tion of species was made by the visualization of the aspect of
the colony—presence or absence of cord formation—due to
the high sensitivity and specificity of this method [18, 19].
Demographic, clinical, laboratorial, pharmacy, and sur-
vival data were collected by chart review. Fever was defined as
an axilar temperature≥38.0◦C. Information on concomitant
AIDS-related opportunistic infections was collected accord-
ing to CDC lists [20].
Laboratory data were included, if the sample was
collected during the first seven days of hospitalization.
CD4 cell count and viral loads were included if they
had been determined within six months of hospitalization.
Antiretroviral therapy was considered the use of one or more
drugs with activity against HIV. Highly active antiretroviral
therapy was considered the use of a combination of three
or more antiretroviral drugs for HIV therapy. Adequate
antituberculous therapy was the use of at least three active
drugs against TB for at least seven days, at any time during
hospitalization.
2.3. Statistical Analysis. A descriptive analysis of the variables
collected from each patient was performed. Continuous
variables are shown as median values and the dispersion
measurement as range values. The chi-squared test or Fisher’s
exact test were used for univariate analysis of selected cat-
egorical variables. Associations were considered statistically
significant when P value was ≤.05. Multivariate hazard
ratios (HR), along with 95% confidence intervals (CI), were
calculated using the Cox proportional hazards regression
model. We included in the final model, the variables with P-
value≤.05 by univariate analysis. Survival analysis was based
on Kaplan-Meier method and comparisons of survival curves
were made by the log-rank test. Data were analyzed in SPSS
16.0 version program.
3. Results
Eighty-two patients with disseminated tuberculosis were
identified. Two patients (1.5%) were excluded from the
analysis for lack of data. All the patients had clinical or
immunological diagnosis of AIDS. The characteristics of
patients are shown in Table 1. Forty-nine patients (61%)
were identified by positive blood cultures, twenty-two
(27.5%) by bone marrow culture, two patients by liver
biopsies culture (2.5%), five patients (6.5%) by blood culture
and bone marrow culture, and another two patients (2.5%)
Table 1: Characteristics of the HIV-infected patients with dissemi-
nated tuberculosis.
Median age (range) 33.0 (14–73)
Men (%) 59 (69.5)
Race
White (%) 52 (66)
Black (%) 22 (28)
Other (%) 5 (6)
HIV exposure
Sexual (%) 31 (52.5)
IV drug use (%) 28 (48.5)
Positive Tuberculin Skin Test 2 (5.5)
Previous ART1 (%) 20 (25)
Concomitant opportunistic infection2 (%) 12 (15)
Median length of hospitalization in days (range) 24 (4–367)
Median CD4 in cells/mcL (No. of patients) 39.5 (44)
Median viral load in log/mL (No. of patients) 4.7 (5)
Anti-HCV positive (%) 24 (39.5)
HBsAg positive (%) 6 (10)
Appropriate initial TB therapy (%) 73 (91)
Median time to TB therapy in days (range) 7 (0–53)
Median time to death in days (range) 18.5 (2–86)
Note. MTB, Mycobacterium tuberculosis; IV, intravenous; ART, antiretroviral
therapy.
1Previous use of ART means previous history of ART.
2Opportunistic diseases were as follows: cytomegalovirus infection (N = 3),
Cryptococcus neoformans infection (N = 8), esophageal candidiasis (N = 6),
toxoplasmosis (N = 3), pneumocystis pneumonia (N = 4),Cryptosporidium
spp (N = 2).
by a combination of liver biopsy and bone marrow culture.
The median duration of hospitalization was 24 days.
Eighty-six (N = 69) percent of the patients had an
abnormal X-ray at admission. Sixty-one patients had sputum
analysis. Of these, 32.5% (N = 26) were positive for acid-
fast bacilli.
Fifty-five isolates (68.5%) were tested for resistance
to antituberculous drugs. One isolate was resistant to
rifampicin and pirazinamide, other was resistant to isoni-
azid and streptomycin, and four isolates were resistant to
streptomycin. None of the isolates had multidrug-resistant
tuberculosis (i.e., resistance to isoniazid and rifampicin). Any
drug resistance was not associated with increased patient
mortality (P = .67). Rifampicin, isoniazid and pirazinamide,
was the initial therapy in 83.5% of patients (N = 67). The
median time to therapy was seven days.
In-hospital mortality was 35% (N = 28). Table 2 shows
the univariate analysis related to in-hospital death. Low
median albumin levels, low hematocrit and hemoglobin
levels, high bilirrubin levels, and ICU admission were all
related to in-hospital death on univariate analysis. Fever at
admission and appropriate initial TB therapy were related
to better survival. Considering other clinical presentations—
respiratory symptoms (dyspnea, cough, chest pain), gas-
trintestinal symptoms (nausea, vomiting, abdominal pain,
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Table 2: In-hospital mortality among HIV-infected patients with disseminated tuberculosis.
In-hospital death
Yes No Total P
Male 22 (78.5) 37 (71) 59 (74) .60
Median Age in years (range) 33 (16–73) 33 (14–70) 33 (N = 78) .75
Concomitant opportunistic infection 3 (10.5) 9 (17.5) 12 (15) .53
ICU admission 14 (50) 4 (7.5) 18 (22.5) <.01
Fever at admission 17 (60.5) 50 (96) 67 (84) <.01
Median alkaline phosphatase (U/L) 601 401 426 (N = 71) .58
(range) (62–2539) (50–4991)
Median ALT (U/L) 47 43 43 (N = 74) .41
(range) (10–389) (9–429)
Median AST (U/L) 100 58 69 (N = 76) .82
(range) (18–544) (12–1575)
Median LDH (U/L) 730 723 725 (N = 71) .91
(range) (227–1627) (172–2329)
Median Bilirrubin (mg/dL) 1.3 0.7 0.8 (N = 72) .02
(range) (0.3–8.1) (0.3–5.2)
Median Hematocrit (%) 23 27 26 (N = 80) .03
(range) (13–34) (8–43)
Median Hemoglobin (g/dL) 7.6 8.9 8.8 (N = 80) .02
(range) (5.5–11.1) (4.6–13.4)
Median Leukocytes (109/L) 4.4 5.1 4.8 (N = 80) .14
(range) (0.5–10.2) (0.5–31.6)
Median Albumin (g/dL) 2.2 2.7 2.6 (N = 67) <.01
(range) (1.4–3.1) (1.7–4.0)
Median Creatinine (mg/dL) 0.9 0.8 0.9 (N = 79) .16
(range) (0.2–2.9) (0.4–1.7)
Median CD4 (cells/mcL) 36 39 39 (N = 44) .92
(range) (1–327) (2–469)
In-hospital HAART1 6 (22.2) 7 (14.3) 13 (17.1) .53
Appropriate initial TB therapy 23 (82.1) 50 (96.2) 73 (91.2) .04
Median time to therapy (days) 6.5 7.0 7.0 (N = 70) .54
(range) (0.0–49.0) (0.0–53.0)
Note. Data are no. (%) of patients, unless otherwise indicated. ICU, Intensive care unit; AFB, acid fast bacilli; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; LDH, lactate dehydrogenase; HAART, highly active antiretroviral therapy; TB, tuberculosis.
1In-hospital HAART means the prescription of HAART during hospital stay, independent of previous ART use.
diarrhea), adenopathies, weight loss, night sweats, headache
or skin lesions—they were not related to death on univariate
analysis. Eighteen patients (33.5%) diagnosed by blood
culture died, compared to 10 patients (38.5%) without
mycobacteremia (P = .80).
The median time to initiating therapy in patients with
fever was 8 days comparing to four days in patients without
fever at admission (P = .27). The median CD4 cell count
was 39 cells/mcL in patients with fever, and 45 cells/mcL in
patients without fever at admission (P = .57). Median levels
of albumin in patients with fever were 2.6 g/dL, and 2.3 g/dL
in patients without fever at admission (P = .21).
As shown in Table 3, the variables included in Cox regres-
sion analysis were those with statistical significance on uni-
variate analysis, and concomitant opportunistic infections
because of their clinical relation to death. By multivariate
analysis, high albumin levels (HR 0.16, CI 0.05–0.56; P < .01)
and fever at admission (HR 0.18, CI 0.06–0.54; P < .01) were
independently related to better survival. Appropriate initial
TB therapy was marginally related to better outcomes (HR
0.25, CI 0.06–1.06; P = .06). Including CD4 counts in the
analysis, high albumin levels (HR 0.25, CI 0.07–0.9; P = .04)
and fever at admission (HR 0.20, CI 0.05–0.9; P = .03)
persisted as independent predictors of survival.
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Figure 1: The Kaplan-Meier survival estimates of HIV-infected patients with disseminated TB (a) in relation to basal albumin levels and (b)
presence of fever at admission.
Kaplan-Meier curves, as shown in Figure 1, included
patients with TB stratified by albumin levels (≤2.7 g/dL
versus >2.7 g/dL) at hospital admission and presence or
absence of fever at admission. Patients with levels of albumin
≤2.7 g/dL had reduced survival rates (P < .01; log-rank test).
The patients with fever at hospital admission had significant
better survival rates (P < .01; log-rank test).
4. Discussion
Disseminated TB is a predictor of worse prognosis for
patients with HIV infection [13, 21]. In our cohort, we
identified albumin levels and fever at admission as additional
independent predictors of mortality. These predictors were
more strongly associated with mortality than recent CD4
count.
In-hospital mortality in our patients was 35%, similar to
prior studies in Thailand and Malawi [22]. Several studies
have addressed predictors of mortality in patients with TB.
Risk factors for mortality include older age, presence of
other comorbid illnesses, emergency department admissions
[23]; corticosteroid use [24]; presence of seizures or coma
in patients with tuberculous meningitis [25]; multiple organ
failure and consolidation on chest radiographs, tuberculous-
destroyed lungs, Acute Physiology and Chronic Health
Evaluation II scores ≥20, and sepsis in patients who suffered
acute respiratory failure [26, 27]; acute renal failure, need
for mechanical ventilation, chronic pancreatitis, sepsis, acute
Table 3: Cox regression analysis. Predictors of in-hospital mortality






Fever at admission 0.18 0.06–0.54 <.01
High albumin levels 0.16 0.05–0.56 <.01
Appropriate initial TB therapy 0.25 0.06–1.06 .06




Low hemoglobin levels 1.06 0.82–1.36 .64
ICU admission 0.98 0.33–2.57 .97
Note. HR, hazard ratio for hospital death; ICU, intensive care unit; TB,
tuberculosis. High or low levels were per 1 g/dL change for albumin and
hemoglobin and per 1 mg/dL for bilirrubins.
respiratory distress syndrome, and nosocomial pneumonia
in patients admitted to the ICU [28]; None of these studies
addressed specifically risk factors for death in patients with
disseminated tuberculosis.
Grinsztejn et al. reported that the in-hospital mortality
was higher among patients with mycobacterial bacteremia
compared to patients without bacteremia, in their study of
42 patients with M. avium and M. tuberculosis infection
[12]. In our study, the patients had a priori the diagnosis of
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disseminated disease. Mycobacteremia per se was not related
to worse prognosis when compared to patients without MTB
bacteremia.
Low levels of albumin (≤2.7 mg/dL) during the first
seven days in the hospital were an independent predictor
of in-hospital death in our patients with disseminated TB.
In the EuroSida risk score study and in the study by Sacks
et al., body mass index has been implicated with disease
progression and death [29, 30]. Matos and Moreira Lemos
reported that serum albumin levels were associated with in-
hospital death in a 373-person Brazilian TB cohort with 9%
HIV coinfection and without disseminated TB disease [10].
Another study in Israel [25] found that cachexia and lower
albumin levels were related to mortality on multivariate
analysis. In the Israeli study, 49 (11%) patients were infected
with HIV. Furthermore, hypoalbuminaemia is a marker of
severe malnutrition and was a predictor of low CD4 counts
in HIV-negative TB patients [31].
Several cytokines have the capacity to induce fever and
play an important role in the modulation of the immune
response. The list of pyrogenic cytokines includes, among
others, interleukin (IL)–1, (TNF)-alpha, IL-6, and IFN-
gamma [32]. Secretion of these proinflammatory cytokines
results in fever and the general constitutional symptoms
associated with MTB as a result of the active adaptive cell-
mediated immune response to MTB. This adaptive response
is lead by IFN-gamma secreted by antigen specific T-helper
Type 1 (Th1) cells. Several studies have demonstrated that
IFN-gamma levels in MTB patients correlate with fever
[33, 34]. Thus, the presence of fever likely represents some
capacity to mount a partial immune response to MTB,
despite the advanced immunosuppression. Hiraki et al.
showed that the pleural fluid concentrations of IL-12, IL-18,
and IFN-gamma in tuberculosis patients were correlated to
high fever (>38◦C) [35].
Patients with fever at admission had better in-hospital
outcomes in our study. Our patients were severely immunos-
suppressed (median CD4 39.5 cells/mcL), but only 44
patients had CD4 T cells measured. Although fever was not
related to CD4 cell count in our sample and we did not
evaluate levels of cytokines and IFN-gamma, the presence
of fever at admission could indicate the patients with better
immune response against MTB and, consequently, predict
those with better outcomes.
Considering that most patients (91.5%) were adequately
treated following standard guidelines, the short median time
to initiate therapy after the diagnosis, the good in-hospital
compliance to anti-TB medication, and the low level of
drug resistance (3.5%) to first-line tuberculostatic agents,
we can state that our patients seemed to have an aggressive
form of disease and/or were diagnosed in their late stage of
disseminated tuberculosis.
Our study has the limitations related to a single-site
retrospective cohort study. Firstly, the selection bias: we
included only patients with positive cultures for TB, possibly
excluding patients with less severe disease, in which blood
cultures were less likely to be obtained. Moreover, the
missing data, related to the retrospective review, reduced the
sample size in the multivariate analysis, which could result
in overfitting problem (high number of variables included
in relation to events) in the Cox regression analysis. Finally,
the observational design precludes us to make definite
conclusions about specific TB therapy and use of HAART in
relation to outcome.
5. Conclusions
Disseminated TB was associated with a high in-hospital
mortality rate, despite adequate therapy, state-of-the-art
diagnostics, and clinical care. For this reason, we emphasize
the importance of HIV testing, access to antiretroviral
therapy, and screening and treatment of latent tuberculosis
infection in order to prevent the disease and mortality
in patients with AIDS. Low basal albumin levels were
independently related to in-hospital mortality, and fever at
admission was related to better prognosis in HIV-infected
patients with disseminated TB and AIDS.
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